# EDGAR Filing Document

**Accession Number:** 0001726029
**File Stem:** 0000921895-25-002765
**Filing Date:** 2025-10
**Character Count:** 21053
**Document Hash:** 8988fe2b9dc34cf164466bb7953ad5de
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002765.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0000921895-25-002765

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251015

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kariv Tomer
- **CENTRAL INDEX KEY:** 0001568077

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401719

**MAIL ADDRESS:**
- **STREET 1:** C/O ARNO THERAPEUTICS, INC.
- **STREET 2:** 200 ROUTE 31 NORTH, SUITE 104
- **CITY:** FLEMINGTON
- **STATE:** NJ
- **ZIP:** 08822
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nussbaum Ran
- **CENTRAL INDEX KEY:** 0001609805

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401718

**MAIL ADDRESS:**
- **STREET 1:** C/O KITE PHARMA, INC.
- **STREET 2:** 2225 COLORADO AVENUE
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax (China) IV L.P.
- **CENTRAL INDEX KEY:** 0001726030

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401722

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax (Cayman) IV L.P.
- **CENTRAL INDEX KEY:** 0001726029

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401723

**BUSINESS ADDRESS:**
- **STREET 1:** 4 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 4 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax Late Stage GP Ltd.
- **CENTRAL INDEX KEY:** 0001793770

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401720

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET
- **STREET 2:** BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** L3 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET
- **STREET 2:** BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** L3 46140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax (Israel) IV, L.P.
- **CENTRAL INDEX KEY:** 0001726039

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401724

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax Management 4 G.P. (2015) Ltd.
- **CENTRAL INDEX KEY:** 0001726334

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401725

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET, BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** 46140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pontifax Late Stage Fund L.P.
- **CENTRAL INDEX KEY:** 0001793769

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39264
- **FILM NUMBER:** 251401721

**BUSINESS ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET
- **STREET 2:** BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** L3 46140
- **BUSINESS PHONE:** 972-9-9725617

**MAIL ADDRESS:**
- **STREET 1:** 14 SHENKAR STREET
- **STREET 2:** BEIT OFEK
- **CITY:** HERZLIYA PITUACH
- **STATE:** L3
- **ZIP:** L3 46140
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Keros Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001664710
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811173868
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1050 WALTHAM STREET, SUITE 302
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 617-314-6297

**MAIL ADDRESS:**
- **STREET 1:** 1050 WALTHAM STREET, SUITE 302
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax Management 4 G.P. (2015) Ltd.<br><sub>(Last) (First) (Middle)</sub><br>14 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax (Israel) IV, L.P.<br><sub>(Last) (First) (Middle)</sub><br>14 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax (Cayman) IV L.P.<br><sub>(Last) (First) (Middle)</sub><br>4 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax (China) IV L.P.<br><sub>(Last) (First) (Middle)</sub><br>14 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax Late Stage Fund L.P.<br><sub>(Last) (First) (Middle)</sub><br>14 SHENKAR STREET<br>BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pontifax Late Stage GP Ltd.<br><sub>(Last) (First) (Middle)</sub><br>14 SHENKAR STREET<br>BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kariv Tomer<br><sub>(Last) (First) (Middle)</sub><br>C/O PONTIFAX MANAGEMENT 4 GP (2015) LTD.<br>14 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nussbaum Ran<br><sub>(Last) (First) (Middle)</sub><br>C/O PONTIFAX MANAGEMENT 4 GP (2015) LTD.<br>14 SHENKAR STREET, BEIT OFEK<br><sub>(Street)</sub><br>HERZLIYA PITUACH, L3 46140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Keros Therapeutics, Inc. [ KROS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock, $0.0001 par value per share | 2025-10-15 |  | S |  | 2284612 | D | $17.7500 | 0 | I | By Pontifax (Israel) IV, L.P.<sup>(1)</sup> |
| Common Stock, $0.0001 par value per share | 2025-10-15 |  | S |  | 1121045 | D | $17.7500 | 0 | I | By Pontifax (Cayman) IV, L.P.<sup>(2)</sup> |
| Common Stock, $0.0001 par value per share | 2025-10-15 |  | S |  | 1226412 | D | $17.7500 | 0 | I | By Pontifax (China) IV, L.P.<sup>(3)</sup> |
| Common Stock, $0.0001 par value per share | 2025-10-15 |  | S |  | 155262 | D | $17.7500 | 0 | I | By Pontifax Late Stage Fund, L.P.<sup>(4)</sup> |
| Common Stock, $0.0001 par value per share |  |  |  |  |  |  |  | 5250 | I | By Tomer Kariv<sup>(5)</sup> |
| Common Stock, $0.0001 par value per share |  |  |  |  |  |  |  | 5250 | I | By Ran Nussbaum<sup>(5)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

(2) The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

(3) The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

(4) The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein.

(5) In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings.

**Signature:** Pontifax Management 4 G.P. (2015) Ltd., By: /s/ Tomer Kariv, Chief Executive Officer  
**Date:** 2025-10-17

**Signature:** Pontifax (Israel) IV L.P., By: /s/ Tomer Kariv, Chief Executive Officer  
**Date:** 2025-10-17

**Signature:** Pontifax (Cayman) IV L.P., By: /s/ Tomer Kariv, Chief Executive Officer  
**Date:** 2025-10-17

**Signature:** Pontifax (China) IV L.P., By: /s/ Tomer Kariv, Chief Executive Officer  
**Date:** 2025-10-17

**Signature:** Pontifax Late Stage Fund, L.P., By: /s/ Asaf Shinar, Chief Financial Officer  
**Date:** 2025-10-17

**Signature:** Pontifax Late Stage GP Ltd., By: /s/ Asaf Shinar, Chief Financial Officer  
**Date:** 2025-10-17

**Signature:** /s/ Tomer Kariv  
**Date:** 2025-10-17

**Signature:** /s/ Ran Nussbaum  
**Date:** 2025-10-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**